BioPlus is showing strong performance. This is interpreted as being influenced by news that the development of biosimilars is becoming active following the expiration of the patent for Saxenda, the blockbuster obesity treatment from global pharmaceutical company Novo Nordisk.
As of 2:01 PM on the 1st, BioPlus is trading at 5,750 KRW, up 3.05% compared to the previous day.
According to the industry, three global pharmaceutical companies?Viartis, Teva, and Novartis?will launch biosimilars in the United States within this year. These companies reached an agreement to release products starting this year after engaging in patent litigation with Novo Nordisk.
The main ingredient of Saxenda is liraglutide, a GLP-1 receptor agonist that increases insulin secretion from the pancreas and delays gastric emptying to suppress appetite. Like Wegovy, it was initially approved as a diabetes treatment and later approved as an obesity treatment.
Domestically, Pepzin and Handok are preparing biosimilars of Saxenda. Pepzin has decided to co-commercialize biosimilars of Saxenda and Wegovy with BioPlus. BioPlus's strategy is to expand the obesity treatments Saxenda and Wegovy, developed by Pepzin, into beauty-related biopharmaceuticals through this co-commercialization with Pepzin.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
